Approval of guselkumab also would escalate the battle for tens of billions in annual sales among a half-dozen companies that sell powerful injected drugs, produced inside living cells, to treat immune disorders including rheumatoid and juvenile arthritis, Crohn's disease and colitis.

Topics:  crohn   drug   
BING NEWS:
  • Johnson & Johnson’s Tremfya seeks to expand FDA approval for pediatric indications to treat juvenile psoriatic arthritis
    Adult clinical trials found that Tremfya could treat plaque psoriasis by 16 weeks. Follow-up analysis found that roughly 23% of patients remained plaque free for more than 156 weeks. The Latest ...
    12/17/2024 - 12:00 am | View Link
  • AbbVie to acquire Roche spinout Nimble in immune drug deal
    The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target of AbbVie’s injection Skyrizi.
    12/13/2024 - 3:12 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News